Literature DB >> 7018267

Nephrotoxic acute renal failure due to common drugs.

G A Porter, W M Bennett.   

Abstract

Antibiotics are the most common drugs implicated in clinical reports of drug-induced nephrotoxicity. The experimental basis for proposed mechanisms of acute renal failure in association with three groups of antibiotics--aminoglycoside, cephalosporin, and amphotericin B--are reviewed in detail. Proposed mechanisms of antibiotic-induced acute renal tubular necrosis involve either altering plasma membrane permeability or interference with cellular energy derived from mitochondria, For either aminoglycoside or cephalosporin antibiotics, cellular accumulation followed by interruption of mitochondrial respiration is the concept that has greatest support, although the possibility of an induced phospholipidosis involving intracellular lysosomes cannot be excluded. Altered renal tubular cell permeability due to the incorporation of amphotericin B into the pore structure of the plasma membrane is consistent with in vivo observation in either clinical or experimental examples of nephrotoxicity with this agent. The metal cis-platinum, used in treatment of neoplastic disease, has a clearly defined incidence of clinical nephrotoxicity with little insight as to cellular mechanisms. A possible mediation involving cis-platinum reducing the protein-bound sulfhydryl group of renal tissue has been proposed. With the ever increasing potency of modern pharmacologic agents come a rising risk of serious toxic side effects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018267     DOI: 10.1152/ajprenal.1981.241.1.F1

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-1a-dependent manner.

Authors:  Shannon D Whirledge; Jose M Garcia; Roy G Smith; Dolores J Lamb
Journal:  Biol Reprod       Date:  2015-01-28       Impact factor: 4.285

Review 2.  Accidental and iatrogenic causes of acute kidney injury.

Authors:  Katherine Twombley; Michel Baum; Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

3.  End Stage Renal Disease: Not a Contraindication for Minor Oral Surgery-Protocol for the Management of Oral Surgery patients with ESRD on Hemodialysis.

Authors:  Sneha Pendem; G Lakshmi Narayana; Poornima Ravi
Journal:  J Maxillofac Oral Surg       Date:  2016-07-28

4.  Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits.

Authors:  N Brion; J Barge; I Godefroy; F Dromer; C Dubois; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats.

Authors:  G Laurent; P Maldague; M B Carlier; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

6.  Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine.

Authors:  D Antoniskis; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  Effect of some simple manoeuvres on the course of acute renal failure after gentamycin treatment in rats.

Authors:  J Heller
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

8.  Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans.

Authors:  A Contrepois; N Brion; J J Garaud; F Faurisson; F Delatour; J C Levy; J C Deybach; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 9.  Toxicological evaluation of cyclosporin A.

Authors:  B Ryffel; P Donatsch; M Madörin; B E Matter; G Rüttimann; H Schön; R Stoll; J Wilson
Journal:  Arch Toxicol       Date:  1983-06       Impact factor: 5.153

10.  Acute Renal Failure Induced by Chinese Herbal Medication in Nigeria.

Authors:  Effiong Ekong Akpan; Udeme E Ekrikpo
Journal:  Case Rep Med       Date:  2015-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.